CD274 and neoplasm: Given the aggressive clinical behavior and limited responsiveness to standard cytotoxic regimens, early integration of ICIs may offer a therapeutic advantage, particularly in tumors with elevated PD-L1 expression or high tumor mutational burden (TMB) [28,29].